Marita Stevens

1.4k citations

38 papers · 985 indexed · h-index 18

Co-authors: René Kerstens Herta Crauwels Simon Vanveggel Katia Boven Annemie Buelens Georges Coremans Martine De Pauw Peter Williams
Topics: HIV/AIDS drug development and treatment (21 papers)HIV Research and Treatment (12 papers)Respiratory viral infections research (11 papers)
Cited by: Virology Infectious Diseases Gastroenterology
Journals: Blood Clinical Infectious Diseases The Journal of Infectious Diseases
Partner nations: Belgium United States United Kingdom

In The Last Decade

Marita Stevens

38 papers receiving 955 citations

Peers

Countries citing papers authored by Marita Stevens

Since Specialization

Citations

This map shows the geographic impact of Marita Stevens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marita Stevens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marita Stevens more than expected).

Fields of papers citing papers by Marita Stevens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marita Stevens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marita Stevens. The network helps show where Marita Stevens may publish in the future.

Co-authorship network of co-authors of Marita Stevens

This figure shows the co-authorship network connecting the top 25 collaborators of Marita Stevens. A scholar is included among the top collaborators of Marita Stevens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marita Stevens. Marita Stevens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assessment of Illness Severity in Adults Hospitalized With Acute Respiratory Tract Infection due to Influenza, Respiratory Syncytial Virus, or Human Metapneumovirus 2024 ·Influenza and Other Respiratory Viruses ·Ann R. Falsey,Edward E. Walsh,Stacey L. House,Yannick Vandendijck,Marita Stevens,Eric K. H. Chan,Gabriela Ispas	10
2	CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus 2024 ·Pediatric Drugs ·Fernando Ferrero,Chien‐Yu Lin,Johannes G. Liese,Kléber Giovanni Luz,(unknown),(unknown),Manuel Gijón,Cristina Calvo,(unknown),Teck‐Hock Toh,(unknown),(unknown),Sarah Rusch,(unknown),(unknown),Leen Vijgen,Dymphy Huntjens,(unknown),(unknown),Mohamed Gamil,Marita Stevens,(unknown)	6
3	A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection 2023 ·Clinical Microbiology and Infection ·Anna Nilsson,John Pullman,Piotr Napora,Kléber Giovanni Luz,Anil Kumar Gupta,(unknown),(unknown),Naresh Aggarwal,(unknown),Juliana Ianus,Leen Vijgen,Jane Scott,Rekha Sinha,Sarah Rusch,Dymphy Huntjens,(unknown),Marita Stevens	9
4	Monitoring Severity of Respiratory Syncytial Virus (RSV) in Infants and Young Children Using the Pediatric RSV Electronic Severity and Outcome Rating System (PRESORS): Results of Initial Quantitative Validation 2021 ·Patient Related Outcome Measures ·Christine de la Loge,(unknown),Paul Williams,Sarah Rusch,Marita Stevens,Jane Scott	3
5	Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein Inhibitor 2019 ·Advances in Therapy ·Bart Remmerie,(unknown),Thomas Van Looy,(unknown),Sarah Rusch,Dymphy Huntjens,Marc De Meulder,Marita Stevens	2
6	Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects 2017 ·Clinical Pharmacokinetics ·Dymphy Huntjens,Sivi Ouwerkerk‐Mahadevan,(unknown),Sarah Rusch,Marita Stevens,René Verloes	11
7	Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents 2016 ·The Pediatric Infectious Disease Journal ·Johan Lombaard,Torsak Bunupuradah,Patricia M. Flynn,John Ramapuram,Francis Ssali,Herta Crauwels,Annemie Hoogstoel,Veerle Van Eygen,Marita Stevens	7
8	Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial 2015 ·The Lancet Infectious Diseases ·David A. Margolis,Cynthia Brinson,Graham Smith,Jerome De Vente,Debbie Hagins,Joseph J. Eron,Sandy Griffith,M H St Clair,Marita Stevens,Peter Williams,Susan L. Ford,Britt Stancil,(unknown),Krischan J Hudson,Kimberly Y. Smith,William Spreen	157
9	Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis 2014 ·AIDS Patient Care and STDs ·Georg M. N. Behrens,Bart Rijnders,Mark Nelson,Chloe Orkin,Calvin Cohen,Anthony Mills,Richard Elion,Simon Vanveggel,Marita Stevens,L Rimsky,David Thorpe,(unknown),Kirsten White,Lijie Zhong,(unknown),Susan K. Chuck	23
10	Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults 2014 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·William Spreen,Peter Williams,David M. Margolis,Susan L. Ford,Herta Crauwels,Yu Lou,Elizabeth Gould,Marita Stevens,Stephen C. Piscitelli	96
11	Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies 2013 ·HIV Clinical Trials ·Mark Nelson,Richard Elion,C Cohen,Anthony Mills,Sally Hodder,Sorana Segal‐Maurer,Mark Bloch,Will Garner,Bill Guyer,Scott Williams,(unknown),Simon Vanveggel,H. Deckx,Marita Stevens	46
12	Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less 2013 ·AIDS ·Jean‐Michel Molina,Nathan Clumeck,(unknown),L Rimsky,Simon Vanveggel,Marita Stevens	22
13	Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. 2013 ·PubMed ·Herta Crauwels,Rolf P. G. van Heeswijk,Marita Stevens,Annemie Buelens,Simon Vanveggel,Katia Boven,Richard M. W. Hoetelmans	48
14	Absence of a pharmacokinetic interaction of rilpivirine with the P‐glycoprotein substrate digoxin in healthy volunteers 2012 ·Journal of the International AIDS Society ·Herta Crauwels,H. Deckx,(unknown),Marita Stevens,Richard M. W. Hoetelmans	2
15	Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials 2012 ·Journal of Antimicrobial Chemotherapy ·Mark Nelson,(unknown),Nathan Clumeck,(unknown),(unknown),(unknown),(unknown),Pablo Tebas,Marita Stevens,Annemie Buelens,Simon Vanveggel,Katia Boven,(unknown)	30
16	Preliminary investigations into the interactions between Beet mild yellowing virus (BMYV) and Beet necrotic yellow vein virus (BNYVV) in susceptible and rhizomania-resistant varieties 2005 ·Rothamsted Repository (Rothamsted Repository) ·Marita Stevens,M. J. C. Asher	3
17	Prucalopride Is Effective in Patients with Severe Chronic Constipation in Whom Laxatives Fail to Provide Adequate Relief 2003 ·Digestion ·Georges Coremans,René Kerstens,Martine De Pauw,Marita Stevens	93
18	Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation 2002 ·Alimentary Pharmacology & Therapeutics ·Cornelius E. J. Sloots,Alexander C. Poen,René Kerstens,Marita Stevens,(unknown),Joop C. van Oene,S. G. M. Meuwissen,R. J. F. Felt‐Bersma	73
19	Prucalopride (PRU) is safe and generally well tolerated in elderly patients with chronic constipation (CC) 2000 ·The American Journal of Gastroenterology ·Alan F. Joslyn,Marita Stevens,(unknown),René Kerstens	1
20	Validation of pharmacologically-guided dosing of carboplatin in paediatric patients 1998 ·British Journal of Cancer ·(unknown),Alan V. Boddy,(unknown),CR Pinkerton,Ian Lewis,Marita Stevens,John Imeson,Rachel Hobson,Newell	2

About Marita Stevens

Marita Stevens is a scholar working on Virology, Infectious Diseases and Gastroenterology, having authored 38 papers that have together received 985 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (21 papers), HIV Research and Treatment (12 papers) and Respiratory viral infections research (11 papers). The work is most often cited by research in Virology (451 citations), Infectious Diseases (659 citations) and Gastroenterology (158 citations). Marita Stevens has collaborated with scholars based in Belgium, United States and United Kingdom. Frequent co-authors include René Kerstens, Herta Crauwels, Simon Vanveggel, Katia Boven, Annemie Buelens, Georges Coremans, Martine De Pauw, Peter Williams, Richard M. W. Hoetelmans and Susan L. Ford. Their work appears in journals such as Blood, Clinical Infectious Diseases and The Journal of Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact